Interaction score 7−Cyclopentyl−5−(4−phenoxy)phenyl−7H−pyrrolo [2,3−d] Color coding visualizes automated cluster analysis using a 0.6 height cutoff for the cluster tree and the inclusion of >2 and <10 drugs per cluster. Unique drug identifiers for compounds in the LOPAC library as supplied by Sigma as well as compound names are depicted (see also Figure S9 . Association between clustering of compounds as shown in Fig 5A and respective interaction spectra for drugs within clusters. While in some instances the similarity of drug profiles was a result of coordinated subtle covariation across multiple cell lines and phenotypes, in other cases it was driven by the similarity of distinctive phenotypes of individual cell lines. For example, the CK2 inhibitors DMAT and TBBz (cluster C5) affected nuclear shape features specifically in cells with only the wildtype copy of PI3KCA (HCT116 PI3KCA wt +/ mt -). The clustering of the compounds ARP101 and YC-1 in C15 was driven by their distinct phenotypes in cells with only the wildtype copies of CTNNB1 (HCT116 CTNNB1 wt +/ mt -) and PI3KCA (HCT116 PI3KCA wt +/ mt -). The clustering of compounds in C18 was driven by distinctive interactions with MEK1 KO cells. Genotype: data only on cell number using 12 genetic backgrounds; Multiparametric phenotypes: data using image-based phenotypes of one genetic background (parental HCT116; P2); Genotypes and multiparametric phenotypes: interaction profiles derived from both genetic backgrounds and image-based phenotypes. B Resolution index (∆ AUC) which displays the performance with which each strategy separated drugs that share/do not chemical similarity is shown for aforementioned approaches (see methods for details). Figure S12 . The EGFR inhibitor tyrphostin AG555 impairs proteasome function. Tyrphostin AG555 increases Ubiquitin abundance. Western blots of total ubiquitin levels after 24 h treatment with compounds at a concentration of 5 µM in HCT116 cells. Tyrphostin AG555 increases the abundance of Ubiquitin, which indicates proteasome inhibition. The proteasome inhibitors MG132 and bortezomib served as positive controls. EGFR inhibitors AG1478 and DAPH did not increase the abundance of ubiquitin. Representative example of 4 independent experiments is shown.
